PDS Biotechnology Corporation (FRA:EU6)

Germany flag Germany · Delayed Price · Currency is EUR
0.723
+0.076 (11.66%)
Last updated: Dec 4, 2025, 8:07 AM CET
-63.80%
Market Cap 41.95M
Revenue (ttm) n/a
Net Income (ttm) -29.73M
Shares Out n/a
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,200
Average Volume 2,909
Open 0.723
Previous Close 0.648
Day's Range 0.723 - 0.723
52-Week Range 0.609 - 2.094
Beta n/a
RSI 50.71
Earnings Date Mar 26, 2026

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protei... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Employees 24
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol EU6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.